Clinical trials: Sexually Transmitted Infections
HPV Infections
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
A study to evaluate the efficacy, immunogenicity, safety and tolerability of V501 in adult women
- Trial name
- NCT00378560
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 1,021 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus Infection, Stage I Oropharyngeal Squamous Cell Carcinoma
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
This phase II trial studies how well radiation therapy and docetaxel work in treating patients with human papillomavirus (HPV)-related oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Human Papillomavirus Infection, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT01932697
- Testing
- Docetaxel, Hyperfractionation, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Mayo Clinic
HIV Infections
Non-interventional Observational Study With Viramune® in HIV to Evaluate Gender Specific Data
The question that prompted this study is the extent to which results from clinical trials can be translated into everyday practice (external validity).
- Trial name
- NCT01134939
- Where
- 34 sites in Germany
- Volunteers
- 265 people
- Sponsor
- Boehringer Ingelheim
HIV, Sexually Transmitted Diseases
Mobile-Based Application "MyChoices"
This study is testing the acceptability and feasibility of MyChoices, a mobile application (app), to promote HIV testing and pre-exposure prophylaxis (PrEP) uptake among young men who have sex with men (YMSM).
- Conditions
- HIV, Sexually Transmitted Diseases, Pre-exposure Prophylaxis, Risk Reduction
- Trial name
- NCT03179319
- Testing
- MyChoices
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fenway Community Health
Human Immunodeficiency Virus Type 1 (HIV-1)
Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat
The purpose of the study is to compare the pharmacokinetics and bioequivalence of atazanavir in a fixed-dose combination with cobicistat with that of atazanavir coadministered with cobicistat as single agents.
- Trial name
- Atazanavir (NCT01837719)
- Testing
- Atazanavir, Cobicistat, Atazanavir/Cobicistat FDC
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV, AIDS
Resistance Testing to Improve Management of Virologic Failure in Sub-Saharan Africa
The study design is an open-label, randomized controlled trial. The study will be conducted at study sites in Uganda and South Africa.
- Trial name
- REVAMP (NCT02787499)
- Testing
- HIV-1 RNA Resistance Testing
- Where
- 2 sites in South Africa, Uganda
- Volunteers
- 840 people
- Sponsor
- Massachusetts General Hospital
HIV/AIDS, Smoking Cessation
Learn to Quit-HIV Pilot Study
The study team will conduct a feasibility, acceptability, and preliminary efficacy trial comparing Learn to Quit-HIV (n=30) to an app based on U.S.
- Conditions
- HIV/AIDS, Smoking Cessation, Tobacco Use Disorder
- Trial name
- NCT04609514
- Testing
- Learn to Quit-HIV, QuitGuide, Nicotine patch
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Duke University
Acquired Immunodeficiency Syndrome, HIV Infections
Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents
The primary objectives of this study are to evaluate the steady-state pharmacokinetics (PK) and confirm the dose of the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) single-tablet regimen…
- Trial name
- NCT01721109
- Testing
- EVG/COBI/FTC/TDF
- Where
- 18 sites in United States, South Africa and 1 more
- Volunteers
- 50 people
- Sponsor
- Gilead Sciences
Health Knowledge, Attitudes, Practice, Health Risk Behaviors
Like Father Like Son
This purpose of this study is to look at the best way to offer the Like Father Like Son + Spear \& Shield program.
- Trial name
- NCT04119414
- Testing
- Spear and Shield (S&S) Program, Like Father Like Son (LFLS) Program
- Where
- Zambia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Miami
HIV Infection
Aspirin and Antiretroviral Therapy in HIV Infected Patients
The purpose of this study is to examine the effects of HIV treatment (antiretroviral therapy) and aspirin use on risk for cardiovascular disease among HIV infected persons.
- Trial name
- NCT00783614
- Testing
- Aspirin 325mg, Antiretroviral therapy (ART)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Hennepin Healthcare Research Institute
Infection, Human Immunodeficiency Virus
A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects
GW433908 (fosamprenavir; FPV)is a pro-drug of amprenavir (APV) which is more water soluble and can be formulated into a tablet with a reduced pill burden (four 700mg tablets of FPV versus sixteen 150mg capsules daily for APV.
- Trial name
- NCT00296504
- Testing
- fosamprenavir (GW433908), ritonavir
- Where
- 24 sites in United States, Brazil and 6 more
- Volunteers
- 753 people
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus, HIV Infections
A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects
This study is a Phase IIb, randomized, multicentre, parallel group, open-label, study having an overall objective to evaluate the antiviral activity, tolerability, and safety of two intramuscular (IM) dosing regimens of GSK744 LA…
- Trial name
- NCT02120352
- Testing
- CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets
- Where
- 50 sites in United States, Canada and 3 more
- Volunteers
- 309 people
- Sponsor
- ViiV Healthcare
HIV Infections
Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
The purpose of this study was to compare the virologic efficacy and safety of three antiretroviral (ARV) regimens, dolutegravir plus emtricitabine/tenofovir alafenamide, dolutegravir plus emtricitabine/tenofovir disoproxil…
- Trial name
- VESTED (NCT03048422)
- Testing
- Dolutegravir, Emtricitabine/tenofovir alafenamide, Emtricitabine/tenofovir disoproxil fumarate
- Where
- 21 sites in United States, Botswana and 7 more
- Volunteers
- 643 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
The purpose of this study was to determine the washout pharmacokinetics (PK) and safety of in utero/intrapartum exposure to maternal raltegravir (RAL) in infants born to pregnant women with HIV infection who received RAL 400 mg…
- Trial name
- NCT01828073
- Testing
- Raltegravir
- Where
- 19 sites in United States, Brazil and 3 more
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Genital Herpes
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
The purpose of this study is to generate safety and immunogenicity data and establish a proof-of-concept of clinical benefit of the mRNA-1608 vaccine candidate.
- Trial name
- NCT06033261
- Testing
- mRNA-1608, BEXSERO
- Where
- 23 sites in United States
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
HIV Infections
Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV
This is an open-label study to examine the safety and immunogenicity of synthetic DNAs encoding NP-GT8 and IL-12 with or without a TLR-agonist-adjuvanted Env Trimer 4571 boost in adults without HIV.
- Trial name
- NCT05781542
- Testing
- sD-NP-GT8 DNA, IL-12 DNA, Trimer 4571
- Where
- 8 sites in United States, South Africa
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Cardiovascular Disease Risk
Cardiovascular Prevention for Persons With HIV
This study is funded by the American Heart Association. The goal of this research is to prevent early cardiovascular damage before symptoms develop for persons with HIV infection.
- Trial name
- NCT00982189
- Testing
- Pravastatin, Lisinopril
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Hennepin Healthcare Research Institute
Pharyngeal Gonococcal Infection
Gent for Pharyngeal Gonorrhea (GC)
The Centers for Disease Control and Prevention has identified antimicrobial-resistant (AMR) Neisseria gonorrhoeae (NG) as one of the nation's top three urgent AMR threats.
- Trial name
- NCT03632109
- Testing
- gentamicin 360mg IM
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Washington
HIV Infection
Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters
The U.S. Department of Health and Human Services (HHS) guidelines recommend that HIV-infected people who have never received anti-HIV therapy be treated with a triple drug regimen (commonly called combination antiretroviral…
- Trial name
- NCT00851799
- Testing
- Emtricitabine/tenofovir disoproxil fumarate, Ritonavir, Atazanavir
- Where
- 26 sites in United States
- Volunteers
- 334 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Genital Warts, Perianal Warts
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects with External Genital Warts and Perianal Warts
- Trial name
- NCT02462187
- Testing
- NVN1000 8% Gel, NVN1000 16%, Vehicle
- Where
- 15 sites in United States
- Volunteers
- 108 people
- Sponsor
- Novan, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.